Nothing Special   »   [go: up one dir, main page]

PE20142329A1 - Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona - Google Patents

Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona

Info

Publication number
PE20142329A1
PE20142329A1 PE2014000758A PE2014000758A PE20142329A1 PE 20142329 A1 PE20142329 A1 PE 20142329A1 PE 2014000758 A PE2014000758 A PE 2014000758A PE 2014000758 A PE2014000758 A PE 2014000758A PE 20142329 A1 PE20142329 A1 PE 20142329A1
Authority
PE
Peru
Prior art keywords
phenyl
etoxy
diazaspiro
decan
ona
Prior art date
Application number
PE2014000758A
Other languages
English (en)
Inventor
Neng-Yang Shih
Sunil Paliwal
Frank Guenter
Ingrid Mergelsberg
Mengwei Hu
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38542035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142329(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of PE20142329A1 publication Critical patent/PE20142329A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA FORMA (I) CRISTALINA ANHIDRA DE LA SAL DE HIDROCLORURO DE (5S,8S)-8-[{(1R)-1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-DIAZASPIRO[4.5]DECAN-2-ONA (FORMULA I) QUE PRESENTA UN PATRON DE DIFRACCION DE POLVO DE RAYOS X QUE TIENE PICOS PRESENTES EN LOS ANGULOS DE DIFRACCION EN 2 THETA DE: 12,9 (S), 15,4 (S), 17,3 (S), 20,2 (S). TAMBIEN ESTA REFERIDA LAS FORMAS CRISTALINAS (II), (III) Y (IV) DE LA SAL TOSILATO DE (5S,8S)-8-[{(1R)-1-(3,5-BIS-(TRIFLUOROMETIL)FENIL)-ETOXI}-METIL]-8-FENIL-1,7-DIAZASPIRO[4.5]DECAN-2-ONA
PE2014000758A 2006-04-05 2007-04-04 Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona PE20142329A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78928006P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
PE20142329A1 true PE20142329A1 (es) 2015-01-30

Family

ID=38542035

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2011001795A PE20120545A1 (es) 2006-04-05 2007-04-04 Composicion farmaceutica que comprende la forma i cristalina de la sal clorhidrato monohidrato de (5s,8s)-8-[{(1r)-1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4,5]decan-2-ona
PE2007000413A PE20071220A1 (es) 2006-04-05 2007-04-04 Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona y su proceso de preparacion
PE2014000758A PE20142329A1 (es) 2006-04-05 2007-04-04 Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2011001795A PE20120545A1 (es) 2006-04-05 2007-04-04 Composicion farmaceutica que comprende la forma i cristalina de la sal clorhidrato monohidrato de (5s,8s)-8-[{(1r)-1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4,5]decan-2-ona
PE2007000413A PE20071220A1 (es) 2006-04-05 2007-04-04 Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona y su proceso de preparacion

Country Status (16)

Country Link
US (5) US8178550B2 (es)
EP (4) EP2004646B1 (es)
JP (3) JP5352446B2 (es)
CN (2) CN102276606B (es)
AR (1) AR060353A1 (es)
CA (1) CA2648604C (es)
ES (1) ES2584838T3 (es)
HU (2) HUE028908T2 (es)
LT (1) LTPA2017031I1 (es)
MX (1) MX2008012935A (es)
PE (3) PE20120545A1 (es)
PL (1) PL2004646T3 (es)
PT (1) PT2004646T (es)
SG (2) SG170838A1 (es)
TW (1) TWI363058B (es)
WO (1) WO2007117486A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
MX2008012935A (es) 2006-04-05 2008-10-15 Schering Corp Sales de clorhidrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etox i}-metil]-8-fenil-1,7-diaza-spiro[4,5]decan-2-ona y su procedmiento de preparacion.
SG10201500028RA (en) 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
AR066191A1 (es) 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AU2009289598B2 (en) 2008-09-05 2014-09-11 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
RU2642234C2 (ru) * 2009-08-14 2018-01-24 ОПКО Хельс, Инк. Композиции антагонистов нейрокинина-1 для внутривенного введения
CN105017251B (zh) * 2015-06-30 2018-06-29 齐鲁制药有限公司 一种nk-1受体拮抗剂的制备方法及其中间体
FR3047665B1 (fr) 2016-02-17 2020-12-11 Pf Medicament Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法
CA3147543A1 (en) * 2019-07-25 2021-01-28 Intervet International B.V. Crystalline form of telmapitant or (5r,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione
EP4125875A1 (en) 2020-04-03 2023-02-08 NeRRe Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
BR112022024208A2 (pt) 2020-06-02 2022-12-20 Nerre Therapeutics Ltd Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0666856B1 (en) 1992-10-28 2000-01-05 MERCK SHARP & DOHME LTD. 4-arylmethyloxymethyl piperidines as tachykinin antagonists
EP0673367A1 (en) 1992-12-14 1995-09-27 MERCK SHARP & DOHME LTD. 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
EP0739336B1 (en) 1994-01-13 1998-08-26 MERCK SHARP & DOHME LTD. Gem-disubstituted azacyclic tachykinin antagonists
WO1997007804A1 (en) 1995-08-28 1997-03-06 Schering Corporation Combination therapy for advanced cancer comprising temozolomide and cisplatin
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
AU735230B2 (en) 1997-07-02 2001-07-05 Merck Sharp & Dohme Corp. Polymorphic form of the tachykinin receptor antagonist 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl) phenyl)ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-5 (-oxo-1H,4H-1,2,4,-triazolo) methylmorpholine
HUP0303154A3 (en) * 2001-02-12 2009-08-28 Teva Pharma New crystal forms of oxcarbazepine and processes for their preparation
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
GB0321256D0 (en) * 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
US20050153999A1 (en) 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
EP1747221B1 (en) 2004-04-07 2009-07-01 Schering Corporation Fused ring nk1 antagonists
ES2632413T3 (es) * 2004-07-01 2017-09-13 Opko Health, Inc. Derivados de piperidina como antagonistas de NK1
MX2007005581A (es) 2004-11-09 2007-05-23 Schering Corp Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente.
WO2007114922A2 (en) 2006-04-05 2007-10-11 Schering Corporation Salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
SG10201500028RA (en) 2006-04-05 2015-02-27 Opko Health Inc Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same
MX2008012935A (es) 2006-04-05 2008-10-15 Schering Corp Sales de clorhidrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etox i}-metil]-8-fenil-1,7-diaza-spiro[4,5]decan-2-ona y su procedmiento de preparacion.
AU2007284851B2 (en) * 2006-08-07 2013-05-09 Palau Pharma, S.A. Crystalline antifungal compounds
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AU2009289598B2 (en) 2008-09-05 2014-09-11 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
RU2642234C2 (ru) * 2009-08-14 2018-01-24 ОПКО Хельс, Инк. Композиции антагонистов нейрокинина-1 для внутривенного введения

Also Published As

Publication number Publication date
JP2013032404A (ja) 2013-02-14
JP2009532472A (ja) 2009-09-10
PE20120545A1 (es) 2012-05-21
TW200815439A (en) 2008-04-01
CN101437821B (zh) 2014-06-04
PL2004646T3 (pl) 2016-12-30
EP2662373A1 (en) 2013-11-13
EP2004646B1 (en) 2016-06-08
WO2007117486A3 (en) 2008-02-14
MX2008012935A (es) 2008-10-15
US20070244142A1 (en) 2007-10-18
US8178550B2 (en) 2012-05-15
EP2676957A1 (en) 2013-12-25
EP2004646A2 (en) 2008-12-24
PE20071220A1 (es) 2007-12-14
US20150210693A1 (en) 2015-07-30
HUE028908T2 (en) 2017-01-30
JP5856944B2 (ja) 2016-02-10
US20100048601A1 (en) 2010-02-25
JP6122411B2 (ja) 2017-04-26
US20190375751A1 (en) 2019-12-12
WO2007117486A2 (en) 2007-10-18
CN101437821A (zh) 2009-05-20
CA2648604A1 (en) 2007-10-18
JP5352446B2 (ja) 2013-11-27
LTPA2017031I1 (lt) 2017-11-10
TWI363058B (en) 2012-05-01
ES2584838T3 (es) 2016-09-29
PT2004646T (pt) 2016-07-14
US20130281477A1 (en) 2013-10-24
US8470842B2 (en) 2013-06-25
AR060353A1 (es) 2008-06-11
SG170838A1 (en) 2011-05-30
US10196394B2 (en) 2019-02-05
CN102276606B (zh) 2013-06-12
HUS1700037I1 (hu) 2017-11-28
JP2014240437A (ja) 2014-12-25
SG10201500027TA (en) 2015-02-27
CA2648604C (en) 2016-05-24
CN102276606A (zh) 2011-12-14
EP2662374A1 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
PE20142329A1 (es) Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4.5]decan-2-ona
NO2018029I1 (no) Alogliptin i kombinasjon med metformin, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
UY30327A1 (es) Nuevos compuestos ii
DE602005000208D1 (de) Kraftstoffzufuhrsystem
ECSP088594A (es) Compuestos de piperazina con efecto herbicida
ECSP109922A (es) Compuestos de pirazol y su uso como inhibidores raf
ME01992B (me) Jedinjenje diarilhidantoina
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
ATE535526T1 (de) 2-methyl-2-ä4-(3-methyl-2-oxo-8-chinolin-3-yl-2 3-dihydro-imidazo ä4,5-cü chinolinyl)- phenylüpropionitril als lipidkinase-hemmer
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
BR112013025881A2 (pt) composto representado pela fórmula geral (i), composto ou um sal do mesmo, inibidor deagregação tau, inibidor de b-secretase, inibidor de agregação de b-proteína amiloide, composição farmacêutica, preparação oral ou parenteral e composto representado pela fórmula geral (ii)
ECSP099571A (es) Derivados pirazólicos como inhibidores de la 11-beta-hsd1
RS53688B1 (en) 1,2,5-OXADIAZOLES AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
UY31140A1 (es) Compuestos de piperazina con accion herbicida
CR10156A (es) Metodos para preparar alcoholes sulfonamida sustituidos e intermediarios de estos
ECSP099565A (es) Compuesto de 2-amino pirimidina
EA200702039A1 (ru) 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны
ATE523219T1 (de) Einweginjektor mit dauergeladenem federenergiespeicher
WO2011098408A3 (de) Hydrazin-substituierte anthranilsäurederivate
UY30001A1 (es) Alquilsulfonamida quinolinas
DE502004006660D1 (de) Verdampfungseinheit f r einen kraftstofffilter
UY29804A1 (es) Quinolinas de alquilnitrilo
DE502005002244D1 (de) Organosiliciumverbindungen mit einer maskierten isocyanatgruppe
EP1751844A4 (en) PIEZOELECTRIC GENERATOR SYSTEM WITH ENERGY STORAGE
DE602006011941D1 (de) Speicherkraftstoffeinspritzsystem

Legal Events

Date Code Title Description
FC Refusal